Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes

Stefania d'Atri, Luigina Romani, Enzo Bonmassar, Ursula Grohmann, Maria Tricarico, Stephen E. Christmas, Michael Moore

Research output: Contribution to journalArticle

Abstract

Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.

Original languageEnglish
Pages (from-to)569-579
Number of pages11
JournalInternational Journal of Immunopharmacology
Volume16
Issue number7
DOIs
Publication statusPublished - 1994

Fingerprint

Triazenes
Lymphocytes
Cytotoxic T-Lymphocytes
Pharmaceutical Preparations
Neoplasms
Tumor Cell Line
Immune Sera
Lymphoma
Transplantation
Cell Membrane
Carcinoma
T-Lymphocytes
Antigens
Cell Line

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes. / d'Atri, Stefania; Romani, Luigina; Bonmassar, Enzo; Grohmann, Ursula; Tricarico, Maria; Christmas, Stephen E.; Moore, Michael.

In: International Journal of Immunopharmacology, Vol. 16, No. 7, 1994, p. 569-579.

Research output: Contribution to journalArticle

d'Atri, Stefania ; Romani, Luigina ; Bonmassar, Enzo ; Grohmann, Ursula ; Tricarico, Maria ; Christmas, Stephen E. ; Moore, Michael. / Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes. In: International Journal of Immunopharmacology. 1994 ; Vol. 16, No. 7. pp. 569-579.
@article{8fd65bfaf1514d859a1e4de8387f8cec,
title = "Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes",
abstract = "Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.",
author = "Stefania d'Atri and Luigina Romani and Enzo Bonmassar and Ursula Grohmann and Maria Tricarico and Christmas, {Stephen E.} and Michael Moore",
year = "1994",
doi = "10.1016/0192-0561(94)90108-2",
language = "English",
volume = "16",
pages = "569--579",
journal = "International Journal of Immunopharmacology",
issn = "0192-0561",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes

AU - d'Atri, Stefania

AU - Romani, Luigina

AU - Bonmassar, Enzo

AU - Grohmann, Ursula

AU - Tricarico, Maria

AU - Christmas, Stephen E.

AU - Moore, Michael

PY - 1994

Y1 - 1994

N2 - Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.

AB - Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.

UR - http://www.scopus.com/inward/record.url?scp=0028301085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028301085&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(94)90108-2

DO - 10.1016/0192-0561(94)90108-2

M3 - Article

C2 - 7928005

AN - SCOPUS:0028301085

VL - 16

SP - 569

EP - 579

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

SN - 0192-0561

IS - 7

ER -